Compare Schwab US Large Cap Growth ETF (SCHG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs 10X Genomics Inc — how do they compare? Schwab US Large Cap Growth ETF trades at $36.65 (market cap $65.01B), while 10X Genomics Inc trades at $79.3 (market cap $10.07B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 6.5× 10X Genomics Inc's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Large Cap Growth ETF for 50 Days and 10X Genomics Inc for 92 Days on average.
| SCHG | TXG | |
|---|---|---|
Market Cap | $65.01B | $10.07B |
Volume | 8,554,399 | 5,657,286 |
Sector | Sector/Thematic | Health |
52-Week High | $36.93 | $97.74 |
52-Week Low | $28.10 | $11.48 |
Typical Hold Time | 50 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $36.87, down 0.16% with a bullish technical outlook from moving averages but bearish oscillators. The ETF maintains strong growth exposure with low expense ratios, though recent news highlights concentration risks in top holdings. Dividend activity remains minimal with a $0.04 distribution scheduled for September 2026.
Growth ETF positioning favors long-term investors despite near-term overbought signals. Key risks include heavy concentration in megacap tech stocks and potential valuation compression. Analyst sentiment remains positive for strategic allocations to large-cap growth exposure with disciplined entry points.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
